Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Leukemia

Retrieve available abstracts of 442 articles:
HTML format
Text format



Single Articles


    May 2018
  1. CHEUNG LC, Tickner J, Hughes AM, Skut P, et al
    New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
    Leukemia. 2018 May 8. pii: 10.1038/s41375-018-0144.
    PubMed     Text format     Abstract available


    April 2018
  2. PATNAIK MM, Pierola AA, Vallapureddy R, Yalniz FF, et al
    Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.
    Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0143.
    PubMed     Text format    


  3. HUITING LN, Samaha Y, Zhang GL, Roderick JE, et al
    UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response.
    Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0141.
    PubMed     Text format     Abstract available


  4. XIAO W, Rampal R, Zhang Y, Cimera R, et al
    JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.
    Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0145.
    PubMed     Text format    


  5. KAYSER S, Schlenk RF, Platzbecker U
    Management of patients with acute promyelocytic leukemia.
    Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0139.
    PubMed     Text format     Abstract available


  6. GARCIA EG, Iyer S, Garcia SP, Loontiens S, et al
    Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0130.
    PubMed     Text format    


  7. RENNEVILLE A, Attias P, Thomas X, Bally C, et al
    Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0137.
    PubMed     Text format    


  8. DE BIE J, Demeyer S, Alberti-Servera L, Geerdens E, et al
    Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0127.
    PubMed     Text format     Abstract available


  9. PASCHKA P, Schlenk RF, Weber D, Benner A, et al
    Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
    Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0129.
    PubMed     Text format     Abstract available


  10. STUDENCKA-TURSKI M, Maubach G, Feige MH, Naumann M, et al
    Constitutive activation of nuclear factor kappa B-inducing kinase counteracts apoptosis in cells with rearranged mixed lineage leukemia gene.
    Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0128.
    PubMed     Text format    


  11. WARTIOVAARA-KAUTTO U, Hirvonen EAM, Pitkanen E, Heckman C, et al
    Germline alterations in a consecutive series of acute myeloid leukemia.
    Leukemia. 2018 Apr 10. pii: 10.1038/s41375-018-0049.
    PubMed     Text format    


  12. CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
    Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
    Leukemia. 2018 Apr 7. pii: 10.1038/s41375-018-0032.
    PubMed     Text format    


  13. HU T, Wu Q, Chong Y, Qin H, et al
    FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
    PubMed     Text format     Abstract available


  14. PATNAIK MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, et al
    A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0121.
    PubMed     Text format    


    March 2018
  15. HOSSEINI MM, Kurtz SE, Abdelhamed S, Mahmood S, et al
    Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
    Leukemia. 2018 Mar 29. pii: 10.1038/s41375-018-0112.
    PubMed     Text format     Abstract available


  16. THAN H, Qiao Y, Huang X, Yan D, et al
    Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.
    Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0050.
    PubMed     Text format    


  17. HOJJAT-FARSANGI M, Daneshmanesh AH, Khan AS, Shetye J, et al
    First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
    Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0113.
    PubMed     Text format    


  18. THI NGOC PC, Tan SH, Tan TK, Chan MM, et al
    Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0110.
    PubMed     Text format     Abstract available


  19. GHIA P, Rawstron A
    Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
    Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0109.
    PubMed     Text format     Abstract available


  20. KUCHENBAUER F, Buske C
    Revisiting thrombocytopenia in acute promyelocytic leukemia.
    Leukemia. 2018 Mar 23. pii: 10.1038/s41375-018-0105.
    PubMed     Text format    


  21. RUDAT S, Pfaus A, Cheng YY, Holtmann J, et al
    RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
    Leukemia. 2018 Mar 22. pii: 10.1038/s41375-018-0102.
    PubMed     Text format     Abstract available


  22. GENTILE M, Shanafelt TD, Reda G, Mauro FR, et al
    Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
    Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0100.
    PubMed     Text format    


  23. BURNS MA, Liao ZW, Yamagata N, Pouliot GP, et al
    Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0097.
    PubMed     Text format     Abstract available


  24. SUN W, Malvar J, Sposto R, Verma A, et al
    Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
    Leukemia. 2018 Mar 15. pii: 10.1038/s41375-018-0094.
    PubMed     Text format     Abstract available


  25. QIN YZ, Huang XJ, Zhu HH
    Identification of a novel CPSF6-RARG fusion transcript in acute myeloid leukemia resembling acute promyelocytic leukemia.
    Leukemia. 2018 Mar 14. pii: 10.1038/s41375-018-0095.
    PubMed     Text format    


  26. GUNNARSSON R, Dilorenzo S, Lundin-Strom KB, Olsson L, et al
    Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 12. pii: 10.1038/s41375-018-0092.
    PubMed     Text format     Abstract available


  27. KELLY AD, Madzo J, Madireddi P, Kropf P, et al
    Demethylator phenotypes in acute myeloid leukemia.
    Leukemia. 2018 Mar 7. pii: 10.1038/s41375-018-0084.
    PubMed     Text format     Abstract available


    February 2018
  28. TAWANA K, Drazer MW, Churpek JE
    Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
    Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0051.
    PubMed     Text format     Abstract available


  29. MARUFFI M, Sposto R, Oberley MJ, Kysh L, et al
    Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis.
    Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0058.
    PubMed     Text format     Abstract available


  30. SAUSSELE S, Hehlmann R, Fabarius A, Jeromin S, et al
    Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
    Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0055.
    PubMed     Text format     Abstract available


  31. ALI A, Penneroux J, Dal Bello R Jr, Masse A, et al
    Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.
    Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0076.
    PubMed     Text format    


  32. PETROV JC, Wada M, Pinz KG, Yan LE, et al
    Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0075.
    PubMed     Text format     Abstract available


  33. HNIZDA A, Fabry M, Moriyama T, Pachl P, et al
    Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0073.
    PubMed     Text format     Abstract available


  34. EISFELD AK, Kohlschmidt J, Mrozek K, Blachly JS, et al
    Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0068.
    PubMed     Text format     Abstract available


  35. BICCLER JL, Ostgard LSG, Severinsen MT, Marcher CW, et al
    Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0054.
    PubMed     Text format    


  36. ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
    Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0034.
    PubMed     Text format     Abstract available


  37. GUPTA S, Devidas M, Loh ML, Raetz EA, et al
    Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0039.
    PubMed     Text format     Abstract available


  38. FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
    Chromothripsis in acute myeloid leukemia: biological features and impact on survival.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0035.
    PubMed     Text format     Abstract available


  39. LAVALLEE VP, Chagraoui J, MacRae T, Marquis M, et al
    Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0069.
    PubMed     Text format     Abstract available


  40. DAVER N, Boddu P, Garcia-Manero G, Yadav SS, et al
    Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0070.
    PubMed     Text format     Abstract available


  41. L ABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0033.
    PubMed     Text format     Abstract available


  42. RASCHE M, Zimmermann M, Borschel L, Bourquin JP, et al
    Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0071.
    PubMed     Text format     Abstract available


  43. STRATI P, Ferrajoli A, Wierda WG, Jain N, et al
    Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
    Leukemia. 2018 Feb 20. pii: 10.1038/s41375-018-0059.
    PubMed     Text format    


  44. CRAMER SD, Hixon JA, Andrews C, Porter RJ, et al
    Mutant IL-7Ralpha and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia.
    Leukemia. 2018 Feb 15. pii: 10.1038/s41375-017-0001.
    PubMed     Text format    


  45. SUAREZ-GONZALEZ J, Martinez-Laperche C, Martinez N, Rodriguez-Macias G, et al
    Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis.
    Leukemia. 2018 Feb 5. pii: 10.1038/s41375-018-0042.
    PubMed     Text format    


  46. PENG D, Wang H, Li L, Ma X, et al
    miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0015.
    PubMed     Text format     Abstract available


  47. LA STARZA R, Messina M, Gianfelici V, Pierini V, et al
    High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0031.
    PubMed     Text format    


  48. WINGELHOFER B, Maurer B, Heyes EC, Cumaraswamy AA, et al
    Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0005.
    PubMed     Text format     Abstract available


  49. MALCIKOVA J, Tausch E, Rossi D, Sutton LA, et al
    ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0007.
    PubMed     Text format     Abstract available


    January 2018
  50. SUN X, Ren Y, Gunawan S, Teng P, et al
    Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099.
    Leukemia. 2018 Jan 30. pii: 10.1038/s41375-018-0020.
    PubMed     Text format    


  51. JO S, Lee JH, Mattei JJ, Barrett DM, et al
    Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
    Leukemia. 2018 Jan 5. pii: leu2017312. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    December 2017
  52. GUPTA S, Devidas M, Loh ML, Raetz EA, et al
    Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG).
    Leukemia. 2017 Dec 18. pii: leu2017341. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  53. BU J, Chen A, Yan X, He F, et al
    SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
    Leukemia. 2017 Dec 18. pii: leu2017339. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  54. FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
    Chromothripsis in acute myeloid leukemia: Biological features and impact on survival.
    Leukemia. 2017 Dec 18. pii: leu2017351. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  55. ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
    Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
    Leukemia. 2017 Dec 18. pii: leu2017350. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  56. CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
    Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
    Leukemia. 2017 Dec 12. pii: leu2017349. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  57. TIRADO-GONZALEZ I, Czlonka E, Nevmerzhitskaya A, Soetopo D, et al
    CRISPR/Cas9 edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.
    Leukemia. 2017 Dec 6. pii: leu2017346. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  58. DRIESSEN EMC, de Lorenzo P, Campbell M, Felice M, et al
    Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.
    Leukemia. 2017;31:2854.
    PubMed     Text format     Abstract available


  59. GRZES KM, Swamy M, Hukelmann JL, Emslie E, et al
    Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy.
    Leukemia. 2017;31:2771-2779.
    PubMed     Text format     Abstract available


  60. GARCIA-MANERO G, Sekeres MA, Egyed M, Breccia M, et al
    A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts.
    Leukemia. 2017;31:2799-2806.
    PubMed     Text format     Abstract available


  61. TESIO M, Trinquand A, Ballerini P, Hypolite G, et al
    Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia.
    Leukemia. 2017;31:2594-2600.
    PubMed     Text format     Abstract available


  62. ELDER A, Bomken S, Wilson I, Blair HJ, et al
    Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia.
    Leukemia. 2017;31:2577-2586.
    PubMed     Text format     Abstract available


  63. DELGADO-MARTIN C, Meyer LK, Huang BJ, Shimano KA, et al
    JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
    Leukemia. 2017;31:2568-2576.
    PubMed     Text format     Abstract available


  64. RASCHE M, von Neuhoff C, Dworzak M, Bourquin JP, et al
    Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.
    Leukemia. 2017;31:2807-2814.
    PubMed     Text format     Abstract available


  65. ZHANG H, Reister Schultz A, Luty S, Rofelty A, et al
    Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations.
    Leukemia. 2017;31:2752-2760.
    PubMed     Text format     Abstract available


  66. LYU Y, Lou J, Yang Y, Feng J, et al
    Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.
    Leukemia. 2017;31:2543-2551.
    PubMed     Text format     Abstract available


  67. YOKOTA A, Hirai H, Shoji T, Maekawa T, et al
    Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo.
    Leukemia. 2017;31:2742-2751.
    PubMed     Text format     Abstract available


    November 2017
  68. LABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2017 Nov 28. pii: leu2017337. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  69. NIMMAGADDA SC, Frey S, Edelmann B, Hellmich C, et al
    Bruton's Tyrosine Kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.
    Leukemia. 2017 Nov 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  70. LHERMITTE L, Mejstrikova E, van der Sluijs-Gelling AJ, Grigore GE, et al
    Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.
    Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  71. WALF-VORDERWULBECKE V, Pearce K, Brooks T, Hubank M, et al
    Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
    Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  72. HADZIJUSUFOVIC E, Albrecht-Schgoer K, Huber K, Hoermann G, et al
    Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
    Leukemia. 2017;31:2388-2397.
    PubMed     Text format     Abstract available


  73. PULIKKAN JA, Tenen DG, Behre G
    C/EBPalpha deregulation as a paradigm for leukemogenesis.
    Leukemia. 2017;31:2279-2285.
    PubMed     Text format     Abstract available


  74. LIU X, Rothe K, Yen R, Fruhstorfer C, et al
    A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy.
    Leukemia. 2017;31:2376-2387.
    PubMed     Text format     Abstract available


  75. THIEL VN, Giaimo BD, Schwarz P, Soller K, et al
    Heterodimerization of AML1/ETO with CBFbeta is required for leukemogenesis but not for myeloproliferation.
    Leukemia. 2017;31:2491-2502.
    PubMed     Text format     Abstract available


  76. O'LEARY HA, Capitano M, Cooper S, Mantel C, et al
    DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms.
    Leukemia. 2017;31:2468-2478.
    PubMed     Text format     Abstract available


  77. HOWARD DR, Munir T, McParland L, Rawstron AC, et al
    Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.
    Leukemia. 2017;31:2416-2425.
    PubMed     Text format     Abstract available


  78. SAVINO AM, Sarno J, Trentin L, Vieri M, et al
    The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
    Leukemia. 2017;31:2365-2375.
    PubMed     Text format     Abstract available


  79. KRAMER AC, Kothari A, Wilson WC, Celik H, et al
    Dnmt3a regulates T-cell development and suppresses T-ALL transformation.
    Leukemia. 2017;31:2479-2490.
    PubMed     Text format     Abstract available


  80. ABRAHAM M, Klein S, Bulvik B, Wald H, et al
    The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
    Leukemia. 2017;31:2336-2346.
    PubMed     Text format     Abstract available


  81. HA VL, Luong A, Li F, Casero D, et al
    The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation.
    Leukemia. 2017;31:2503-2514.
    PubMed     Text format     Abstract available


  82. DELL'AVERSANA C, Giorgio C, D'Amato L, Lania G, et al
    miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.
    Leukemia. 2017;31:2315-2325.
    PubMed     Text format     Abstract available


    October 2017
  83. SAID B, Gilles S, Weisdorf D, Rashidi A, et al
    The role of bone marrow morphology in the diagnosis of relapsed acute myeloid leukemia.
    Leukemia. 2017 Oct 31. doi: 10.1038/leu.2017.
    PubMed     Text format    


  84. YAN F, Shen N, Pang JX, Zhao N, et al
    A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target.
    Leukemia. 2017 Oct 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  85. TOPP MS, Stelljes M, Zugmaier G, Barnette P, et al
    Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Oct 9. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  86. JERCHEL IS, Hoogkamer AQ, Aries IM, Steeghs EMP, et al
    RAS pathway mutations as predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Oct 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  87. LI Z, Abraham BJ, Berezovskaya A, Farah N, et al
    APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
    Leukemia. 2017;31:2057-2064.
    PubMed     Text format     Abstract available


  88. MUNIR T, Howard DR, McParland L, Pocock C, et al
    Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
    Leukemia. 2017;31:2085-2093.
    PubMed     Text format     Abstract available


  89. JU HQ, Zhan G, Huang A, Sun Y, et al
    ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
    Leukemia. 2017;31:2143-2150.
    PubMed     Text format     Abstract available


  90. DUELL J, Dittrich M, Bedke T, Mueller T, et al
    Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.
    Leukemia. 2017;31:2181-2190.
    PubMed     Text format     Abstract available


  91. CHEN KH, Wada M, Pinz KG, Liu H, et al
    Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Leukemia. 2017;31:2151-2160.
    PubMed     Text format     Abstract available


    September 2017
  92. FUJITA S, Honma D, Adachi N, Araki K, et al
    Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
    Leukemia. 2017 Sep 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  93. PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
    NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
    Leukemia. 2017 Sep 25. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  94. BENEDETTI D, Tissino E, Pozzo F, Bittolo T, et al
    NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-kB pathways.
    Leukemia. 2017 Sep 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  95. JO S, Lee JH, Mattei JJ, Barrett DM, et al
    Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  96. DEL GIUDICE I, Rigolin GM, Raponi S, Cafforio L, et al
    Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low and very-low risk genetic profile.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  97. NADEU F, Clot G, Delgado J, Martin-Garcia D, et al
    Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  98. HOSPITAL MA, Jacquel A, Mazed F, Saland E, et al
    RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  99. SAKURA T, Hayakawa F, Sugiura I, Murayama T, et al
    High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  100. WAIBEL M, Vervoort SJ, Kong IY, Heinzel S, et al
    Epigenetic targeting of Notch1 driven transcription using the HDACi panobinostat is a potential therapy against T cell acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  101. TAKAO S, Chien W, Madan V, Lin DC, et al
    Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  102. MARNETH AE, Prange KHM, Al Hinai ASA, Bergevoet SM, et al
    C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.
    Leukemia. 2017 Sep 5. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  103. RINKE J, Muller JP, Blaess MF, Chase A, et al
    Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.
    Leukemia. 2017;31:1936-1943.
    PubMed     Text format     Abstract available


  104. KIM T, Tyndel MS, Kim HJ, Ahn JS, et al
    The clonal origins of leukemic progression of myelodysplasia.
    Leukemia. 2017;31:1928-1935.
    PubMed     Text format     Abstract available


  105. SAENZ DT, Fiskus W, Qian Y, Manshouri T, et al
    Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
    Leukemia. 2017;31:1951-1961.
    PubMed     Text format     Abstract available


  106. RONCHINI C, Brozzi A, Riva L, Luzi L, et al
    PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.
    Leukemia. 2017;31:1975-1986.
    PubMed     Text format     Abstract available


    August 2017
  107. DEGRYSE S, de Bock CE, Demeyer S, Govaerts I, et al
    Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Aug 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  108. JYOTSANA N, Sharma A, Chaturvedi A, Scherr M, et al
    RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo.
    Leukemia. 2017 Aug 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  109. ZHAO L, Alkadi H, Kwon EM, Zhen T, et al
    The C-terminal multimerization domain is essential for leukemia development by CBFbeta-SMMHC in a mouse knockin model.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  110. TOFT N, Birgens H, Abrahamsson J, Griskevicius L, et al
    Results of NOPHO ALL2008 treatment for patients 1-45 years with acute lymphoblastic leukemia.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  111. PENA-MARTINEZ P, Eriksson M, Ramakrishnan R, Chapellier M, et al
    Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6 dependent manner.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  112. KUMAR B, Garcia M, Weng L, Jung X, et al
    Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.
    Leukemia. 2017 Aug 17. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  113. ARTESI M, Marcais A, Durkin K, Rosewick N, et al
    Monitoring molecular response in adult t-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality.
    Leukemia. 2017 Aug 16. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  114. HOECHSTETTER MA, Busch R, Eichhorst B, Buhler A, et al
    Early, risk-adapted treatment with fludarabine in binet stage a chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  115. HEHLMANN R, Lauseker M, Saussele S, Pfirrmann M, et al
    Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  116. REITER K, Polzer H, Krupka C, Maiser A, et al
    Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  117. MASCIARELLI S, Capuano E, Ottone T, Divona M, et al
    'Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress'.
    Leukemia. 2017 Aug 4. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  118. RAFIQ S, Purdon TJ, Daniyan AF, Koneru M, et al
    Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
    Leukemia. 2017;31:1788-1797.
    PubMed     Text format     Abstract available


  119. DRENNAN S, D'Avola A, Gao Y, Weigel C, et al
    IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.
    Leukemia. 2017;31:1686-1694.
    PubMed     Text format     Abstract available


    July 2017
  120. KIM HG, LeGrand J, Swindle CS, Nick HJ, et al
    The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  121. YIGIT B, Wang N, Chen SS, Chiorazzi N, et al
    Inhibition of Reactive oxygen species (ROS) limits expansion of chronic lymphocytic leukemia cells.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  122. TEH TC, Nguyen NY, Moujalled DM, Segal D, et al
    Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  123. GIRARDI T, Vereecke S, Sulima SO, Khan Y, et al
    The T-cell leukemia associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  124. XIA F, Zhang Y, Xie L, Jiang H, et al
    B7-H4 enhances the differentiation of murine leukemia-initiating cells via the PTEN/AKT/RCOR2/RUNX1 pathways.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  125. SOPPER S, Mustjoki S, Gjertsen BT, Giles F, et al
    NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  126. AL-SAWAF O, Robrecht S, Bahlo J, Fink AM, et al
    Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.
    Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.
    PubMed     Text format    


  127. BECK D, Thoms JAI, Palu C, Herold T, et al
    A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.
    Leukemia. 2017 Jul 4. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  128. HOURIGAN CS, Gale RP, Gormley NJ, Ossenkoppele GJ, et al
    Measurable residual disease testing in acute myeloid leukaemia.
    Leukemia. 2017;31:1482-1490.
    PubMed     Text format     Abstract available


  129. CUTLER JA, Tahir R, Sreenivasamurthy SK, Mitchell C, et al
    Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.
    Leukemia. 2017;31:1513-1524.
    PubMed     Text format     Abstract available


  130. RIBEIRO ST, Tesio M, Ribot JC, Macintyre E, et al
    Casein kinase 2 controls the survival of normal thymic and leukemic gammadelta T cells via promotion of AKT signaling.
    Leukemia. 2017;31:1603-1610.
    PubMed     Text format     Abstract available


    June 2017
  131. ANGENENDT L, Reuter S, Kentrup D, Benk AS, et al
    An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.
    Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  132. YABE T, Azuma F, Kashiwase K, Matsumoto K, et al
    HLA-DPB1 mismatch induces a graft-versus-leukemia (GVL) effect without severe acute GVHD after single-unit umbilical cord blood transplantation.
    Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  133. TIAO G, Improgo MR, Kasar S, Poh W, et al
    Rare germline variants in ATM are associated with chronic lymphocytic leukemia.
    Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  134. GAIDZIK VI, Weber D, Paschka P, Kaumanns A, et al
    DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
    Leukemia. 2017 Jun 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  135. ZHANG Q, Ball MC, Zhao Y, Balasis M, et al
    Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.
    Leukemia. 2017 Jun 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  136. RIO-MACHIN A, Gomez-Lopez G, Munoz J, Garcia-Martinez F, et al
    The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia.
    Leukemia. 2017 Jun 20. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  137. GODWIN CD, Gale RP, Walter RB
    Gemtuzumab ozogamicin in acute myeloid leukemia.
    Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  138. SANTINI V, Allione B, Zini G, Gioia D, et al
    A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
    Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  139. BURNS A, Alsolami R, Becq J, Timbs A, et al
    Whole genome sequencing of chronic lymphocytic leukemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.
    Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  140. MARTINEZ-CUADRON D, Montesinos P, Vellenga E, Bernal T, et al
    Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
    Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  141. PROMOD ST, Johnson DP, Bennett SE, Dennis EM, et al
    HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Jun 5. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  142. HAHN M, Burckert JP, Luttenberger CA, Klebow S, et al
    Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-kappaB signaling.
    Leukemia. 2017 Jun 1. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  143. USTUN C, Giannotti F, Zhang MJ, Wang HL, et al
    Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.
    Leukemia. 2017;31:1408-1414.
    PubMed     Text format     Abstract available


  144. HERNDON TM, Chen SS, Saba NS, Valdez J, et al
    Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.
    Leukemia. 2017;31:1340-1347.
    PubMed     Text format     Abstract available


  145. YAN F, Shen N, Pang JX, Zhang YW, et al
    Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.
    Leukemia. 2017;31:1434-1442.
    PubMed     Text format     Abstract available


  146. CHENG G, Liu F, Asai T, Lai F, et al
    Loss of p300 accelerates MDS-associated leukemogenesis.
    Leukemia. 2017;31:1382-1390.
    PubMed     Text format     Abstract available


  147. RODMAN C, Almeida-Porada G, George SK, Moon J, et al
    In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells.
    Leukemia. 2017;31:1398-1407.
    PubMed     Text format     Abstract available


  148. CARTER MJ, Cox KL, Blakemore SJ, Turaj AH, et al
    PI3Kdelta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.
    Leukemia. 2017;31:1423-1433.
    PubMed     Text format     Abstract available


    May 2017
  149. HALPERN AB, Othus M, Huebner EM, Buckley SA, et al
    Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  150. HA JS, Do YR, Ki CS, Lee C, et al
    Identification of a novel PML-RARG fusion in acute promyelocytic leukemia.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  151. PATEL B, Przychodzen B, Thota S, Radivoyevitch T, et al
    Genomic determinants of chronic myelomonocytic leukemia.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  152. HEILMANN AM, Schrock AB, He J, Nahas M, et al
    Novel PDGFRB fusions in childhood B and T acute lymphoblastic leukemia.
    Leukemia. 2017 May 29. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  153. MA Z, Zhao X, Huang J, Jia X, et al
    A critical role of periostin in B-cell acute lymphoblastic leukemia.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  154. BERNSON E, Hallner A, Sander FE, Wilsson O, et al
    Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  155. HINZE L, Moricke A, Zimmermann M, Junk S, et al
    Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  156. CHEN L, Mao H, Zhang J, Chu J, et al
    Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
    Leukemia. 2017 May 12. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  157. PAN J, Yang J, Deng B, Zhao X, et al
    High efficacy and safety of low dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
    Leukemia. 2017 May 11. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  158. ROSSETTI C, Picardi E, Ye M, Camilli G, et al
    RNA editing signature during myeloid leukemia cell differentiation.
    Leukemia. 2017 May 9. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  159. HASAN K, Yu J, Chen L, Cui B, et al
    Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
    Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  160. YU J, Chen L, Chen Y, Hasan K, et al
    Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
    Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  161. SLINGER E, Thijssen R, Kater AP, Eldering E, et al
    Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  162. LONG J, Fang WY, Chang L, Gao WH, et al
    Targeting HDAC3, new partner protein of AKT in the reversal of chemo-resistance in acute myeloid leukemia via DNA damage response.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  163. GUNNARSSON N, Hoglund M, Stenke L, Sandin F, et al
    No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia-a population-based study in Sweden.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  164. EIRING AM, Page BDG, Kraft IL, Mason CC, et al
    Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
    Leukemia. 2017;31:1253-1254.
    PubMed     Text format    


  165. LEROY E, Constantinescu SN
    Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition.
    Leukemia. 2017;31:1023-1038.
    PubMed     Text format     Abstract available


  166. KAZIANKA L, Drucker C, Skrabs C, Thomas W, et al
    Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
    Leukemia. 2017;31:1117-1122.
    PubMed     Text format     Abstract available


  167. MALANI D, Murumagi A, Yadav B, Kontro M, et al
    Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
    Leukemia. 2017;31:1187-1195.
    PubMed     Text format     Abstract available


  168. LIU TH, Tang YJ, Huang Y, Wang L, et al
    Expression of the fetal hematopoiesis regulator FEV indicates leukemias of prenatal origin.
    Leukemia. 2017;31:1079-1086.
    PubMed     Text format     Abstract available


    April 2017
  169. CAZZANIGA G, Bisanti L, Randi G, Deandrea S, et al
    Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster.
    Leukemia. 2017 Apr 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  170. ROSENQUIST R, Ghia P, Hadzidimitriou A, Sutton LA, et al
    Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: Updated eric recommendations.
    Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  171. MAEKAWA T, Osawa Y, Izumi T, Nagao S, et al
    Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
    Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  172. KONGTIM P, Adekola K, Milton DR, Ramlal R, et al
    Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Leukemia. 2017 Apr 12. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  173. HAN SH, Kim SH, Kim HJ, Lee Y, et al
    Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.
    Leukemia. 2017 Apr 11. doi: 10.1038/leu.2017.
    PubMed     Text format    


  174. JONES D, Woyach JA, Zhao W, Caruthers S, et al
    PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  175. SILVA P, Neumann M, Schroeder MP, Vosberg S, et al
    Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.
    Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  176. HEATH EM, Chan SM, Minden MD, Murphy T, et al
    Biological and clinical consequences of NPM1 mutations in AML.
    Leukemia. 2017;31:798-807.
    PubMed     Text format     Abstract available


  177. VALENT P, Sotlar K, Blatt K, Hartmann K, et al
    Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
    Leukemia. 2017;31:788-797.
    PubMed     Text format     Abstract available


  178. SCHUTZ C, Inselmann S, Sausslele S, Dietz CT, et al
    Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
    Leukemia. 2017;31:829-836.
    PubMed     Text format     Abstract available


    March 2017
  179. HEROLD S, Kuhn M, Bonin MV, Stange T, et al
    Donor cell leukemia-Evidence for multiple pre-leukemic clones and parallel long term clonal evolution in donor and recipient.
    Leukemia. 2017 Mar 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  180. ANADON C, van Tetering G, Ferreira HJ, Moutinho C, et al
    Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  181. COSSON A, Chapiro E, Bougacha N, Lambert J, et al
    Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: Analysis of the central role of XPO1.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  182. MONTALBAN-BRAVO G, Huang X, Naqvi K, Jabbour E, et al
    A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
    Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
    PubMed     Text format    


  183. WALKER CJ, Eisfeld AK, Genutis LK, Bainazar M, et al
    No evidence for microsatellite instability in acute myeloid leukemia.
    Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  184. KAYSER S, Krzykalla J, Elliott MA, Norsworthy K, et al
    Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  185. ZHOU H, Mak PY, Mu H, Mak DH, et al
    Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  186. EISFELD AK, Mrozek K, Kohlschmidt J, Nicolet D, et al
    The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  187. POZZO F, Bittolo T, Vendramini E, Bomben R, et al
    NOTCH1 mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin-1 and ribosome associated components.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  188. YUAN T, Yang Y, Chen J, Li W, et al
    Regulation of PI3K signaling in T cell acute lymphoblastic leukemia: A novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD.
    Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  189. POULAIN L, Sujobert P, Zylbersztejn F, Barreau S, et al
    High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.
    Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  190. KOEFFLER HP, Leong G
    Preleukemia: one name, many meanings.
    Leukemia. 2017;31:534-542.
    PubMed     Text format     Abstract available


  191. SAENZ DT, Fiskus W, Manshouri T, Rajapakshe K, et al
    BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
    Leukemia. 2017;31:678-687.
    PubMed     Text format     Abstract available


  192. QAZILBASH MH, Wieder E, Thall PF, Wang X, et al
    PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
    Leukemia. 2017;31:697-704.
    PubMed     Text format     Abstract available


  193. STRUSKI S, Lagarde S, Bories P, Puiseux C, et al
    NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
    Leukemia. 2017;31:565-572.
    PubMed     Text format     Abstract available


  194. STENGEL A, Kern W, Haferlach T, Meggendorfer M, et al
    The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
    Leukemia. 2017;31:705-711.
    PubMed     Text format     Abstract available


  195. MCCRACKEN AN, McMonigle RJ, Tessier J, Fransson R, et al
    Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
    Leukemia. 2017;31:669-677.
    PubMed     Text format     Abstract available


  196. EDELMANN J, Tausch E, Landau DA, Robrecht S, et al
    Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
    Leukemia. 2017;31:734-738.
    PubMed     Text format    


    February 2017
  197. HUSSEIN K, Stucki-Koch A, Gohring G, Kreipe H, et al
    Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukemia with bone marrow fibrosis.
    Leukemia. 2017 Feb 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  198. HAN SH, Kim SH, Kim HJ, Lee Y, et al
    Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.
    Leukemia. 2017 Feb 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  199. LEHMANN S, Deneberg S, Antunovic P, Rangert-Derolf A, et al
    Early death rates remain high in high-risk APL. Update from the Swedish acute leukemia registry 1997-2013.
    Leukemia. 2017 Feb 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  200. CHATURVEDI A, Herbst L, Pusch S, Klett L, et al
    Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
    Leukemia. 2017 Feb 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  201. KOBAYASHI M, Chen S, Bai Y, Yao C, et al
    Phosphatase PRL2 promotes AML1-ETO-induced acute myeloid leukemia.
    Leukemia. 2017 Feb 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  202. HOCHHAUS A, Masszi T, Giles FJ, Radich JP, et al
    Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study.
    Leukemia. 2017 Feb 20. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  203. SUGINO N, Kawahara M, Tatsumi G, Kanai A, et al
    A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.
    Leukemia. 2017 Feb 17. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  204. SHIMA Y, Yumoto M, Katsumoto T, Kitabayashi I, et al
    MLL is essential for NUP98-HOXA9-induced leukemia.
    Leukemia. 2017 Feb 17. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  205. RATNAPARKHE M, Hlevnjak M, Kolb T, Jauch A, et al
    Genomic profiling of acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis.
    Leukemia. 2017 Feb 15. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  206. KOBAYASHI S, Kobayashi A, Osawa Y, Nagao S, et al
    Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation.
    Leukemia. 2017 Feb 14. doi: 10.1038/leu.2017.
    PubMed     Text format    


  207. ETXABE A, Lara-Castillo MC, Cornet-Masana JM, Banus-Mulet A, et al
    Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem-cell functionality: A promising novel therapeutic target.
    Leukemia. 2017 Feb 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  208. DANG J, Nance S, Ma J, Cheng J, et al
    AMKL chimeric transcription factors are potent inducers of leukemia.
    Leukemia. 2017 Feb 8. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  209. WANG M, Lindberg J, Klevebring D, Nilsson C, et al
    Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.
    Leukemia. 2017 Feb 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  210. COPPE A, Andersson EI, Binatti A, Gasparini VR, et al
    Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach.
    Leukemia. 2017 Feb 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  211. MEDEIROS BC, Fathi AT, DiNardo CD, Pollyea DA, et al
    Isocitrate dehydrogenase mutations in myeloid malignancies.
    Leukemia. 2017;31:272-281.
    PubMed     Text format     Abstract available


  212. BURNETT AK, Russell NH, Hills RK, Kell J, et al
    A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
    Leukemia. 2017;31:310-317.
    PubMed     Text format     Abstract available


    January 2017
  213. CHANAN-KHAN A, Egyed M, Robak T, de Oliveira FA, et al
    Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).
    Leukemia. 2017 Jan 31. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  214. ROSSIG C, Pule M, Altvater B, Saiagh S, et al
    Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.
    Leukemia. 2017 Jan 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  215. MURPHY EJ, Neuberg DS, Rassenti LZ, Hayes G, et al
    Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.
    Leukemia. 2017 Jan 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  216. BRUNETTI L, Di Battista V, Venanzi A, Schiavoni G, et al
    Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: A shared clonal origin.
    Leukemia. 2017 Jan 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  217. RECKEL S, Hamelin R, Georgeon S, Armand F, et al
    Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
    Leukemia. 2017 Jan 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  218. DENG J, Isik E, Fernandes SM, Brown JR, et al
    Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Leukemia. 2017 Jan 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  219. GUIDUGLI L, Johnson AK, Alkorta-Aranburu G, Nelakuditi V, et al
    Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes.
    Leukemia. 2017 Jan 20. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  220. WATTAD M, Weber D, Dohner K, Krauter J, et al
    Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.
    Leukemia. 2017 Jan 19. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  221. YOSHIDA N, Sakaguchi H, Muramatsu H, Okuno Y, et al
    Germline IKAROS mutation associated with primary immunodeficiency that progressed to T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Jan 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  222. KAROL SE, Larsen E, Cheng C, Cao X, et al
    Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia.
    Leukemia. 2017 Jan 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  223. SCHLENK RF, Frech P, Weber D, Brossart P, et al
    Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.
    Leukemia. 2017 Jan 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  224. BACCARANI M
    Treatment-free remission in chronic myeloid leukemia: Floating between expectation and evidence.
    Leukemia. 2017 Jan 17. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  225. JAHN N, Agrawal M, Bullinger L, Weber D, et al
    Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): A study of the German-Austrian AML study group (AMLSG).
    Leukemia. 2017 Jan 16. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  226. PEIRS S, Frismantas V, Matthijssens F, Van Loocke W, et al
    Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Jan 11. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  227. KELLY AD, Kroeger H, Yamazaki J, Taby R, et al
    A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome.
    Leukemia. 2017 Jan 11. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  228. MEHDIPOUR P, Santoro F, Botrugno OA, Romanenghi M, et al
    HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia.
    Leukemia. 2017 Jan 11. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  229. CUTRONA G, Matis S, Colombo M, Massucco C, et al
    Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: Implication for therapy.
    Leukemia. 2017 Jan 5. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  230. LI YJ, Sun L, Shi Y, Wang G, et al
    PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions.
    Leukemia. 2017 Jan 4. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  231. ISHIYAMA K, Kitawaki T, Sugimoto N, Sozu T, et al
    Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.
    Leukemia. 2017;31:268.
    PubMed     Text format    


    December 2016
  232. ROHRABAUGH S, Kesarwani M, Kincaid Z, Huber E, et al
    Enhanced MAPK signaling is essential for CSF3R induced leukemia.
    Leukemia. 2016 Dec 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  233. ALDOSS I, Bargou RC, Nagorsen D, Friberg GR, et al
    Redirecting T-cells to eradicate B-cell acute lymphoblastic leukemia: Bispecific T-cell engagers and chimeric antigen receptors.
    Leukemia. 2016 Dec 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  234. LIAU WS, Tan SH, Ngoc PC, Wang CQ, et al
    Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia.
    Leukemia. 2016 Dec 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  235. ARRUGA F, Gizdic B, Bologna C, Cignetto S, et al
    Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22.
    Leukemia. 2016 Dec 26. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  236. PATEL VM, Balakrishnan K, Douglas M, Tibbitts T, et al
    Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).
    Leukemia. 2016 Dec 26. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  237. FISHER DA, Malkova O, Engle EK, Miner C, et al
    Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.
    Leukemia. 2016 Dec 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  238. LANG F, Wojcik B, Bothur S, Knecht C, et al
    Plastic CD34 and CD38 expression in adult B-cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations.
    Leukemia. 2016 Dec 13. doi: 10.1038/leu.2016.
    PubMed     Text format    


  239. TASIAN SK, Hurtz C, Wertheim GB, Bailey NG, et al
    High incidence of philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) in older adults with B-ALL.
    Leukemia. 2016 Dec 9. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  240. CHARMSAZ S, Al-Ejeh F, Yeadon T, Miller KJ, et al
    EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
    Leukemia. 2016 Dec 6. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  241. VARDI A, Vlachonikola E, Karypidou M, Stalika E, et al
    Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: High-throughput immunoprofiling supports selection by shared antigenic elements.
    Leukemia. 2016 Dec 1. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  242. YU J, Chen L, Cui B, Wu C, et al
    Cirmtuzumab inhibits Wnt5a-induced Rac1-activation in chronic lymphocytic leukemia treated with ibrutinib.
    Leukemia. 2016 Dec 1. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    November 2016
  243. VESELY C, Frech C, Eckert C, Cario G, et al
    Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.
    Leukemia. 2016 Nov 30. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  244. ILANDER M, Olsson-Stromberg U, Schlums H, Guilhot J, et al
    Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
    Leukemia. 2016 Nov 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  245. BISIO V, Zampini M, Tregnago C, Manara E, et al
    NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: A report from the AIEOP-AML group.
    Leukemia. 2016 Nov 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  246. YOUNG E, Noerenberg D, Mansouri L, Ljungstrom V, et al
    EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
    Leukemia. 2016 Nov 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  247. QUINTAS-CARDAMA A, Hu C, Qutub A, Qiu YH, et al
    p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.
    Leukemia. 2016 Nov 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  248. THOL F, Klesse S, Kohler L, Gabdoulline R, et al
    Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
    Leukemia. 2016 Nov 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  249. CHIEN W, Sun QY, Ding LW, Mayakonda A, et al
    Diagnosis and relapse: Cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD.
    Leukemia. 2016 Nov 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  250. KOBAYASHI M, Bai Y, Chen S, Gao R, et al
    Phosphatase PRL2 promotes oncogenic NOTCH1-induced T cell leukemia.
    Leukemia. 2016 Nov 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  251. JOVANOVIC JV, Chillon MC, Vincent-Fabert C, Dillon R, et al
    The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid sensitive acute promyelocytic leukemia.
    Leukemia. 2016 Nov 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  252. CERELLA C, Gaigneaux A, Mazumder A, Lee JY, et al
    Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia.
    Leukemia. 2016 Nov 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  253. SHEN Y, Park CS, Suppipat K, Mistretta TA, et al
    Inactivation of KLF4 promotes T cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.
    Leukemia. 2016 Nov 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  254. EISFELD AK, Kohlschmidt J, Schwind S, Nicolet D, et al
    Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
    Leukemia. 2016 Nov 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  255. GOLTZ D, Gevensleben H, Grunen S, Dietrich J, et al
    PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia.
    Leukemia. 2016 Nov 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  256. BAER C, Dicker F, Kern W, Haferlach T, et al
    Genetic characterization of MYD88 mutated lymphoplasmacytic lymphoma in comparison to MYD88 mutated chronic lymphocytic leukemia.
    Leukemia. 2016 Nov 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  257. ZHOU C, Martinez E, Di Marcantonio D, Patel-Solanki N, et al
    JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia.
    Leukemia. 2016 Nov 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  258. DAFFLON C, Craig VJ, Mereau H, Grasel J, et al
    Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Leukemia. 2016 Nov 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  259. ESTEY E, Gale RP
    Acute myeloid leukemia therapy and the chosen people.
    Leukemia. 2016 Nov 11. doi: 10.1038/leu.2016.
    PubMed     Text format    


  260. VON DER HEIDE EK, Neumann M, Vosberg S, James AR, et al
    Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients.
    Leukemia. 2016 Nov 11. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  261. STAMATOPOULOS K, Agathangelidis A, Rosenquist R, Ghia P, et al
    Antigen receptor stereotypy in chronic lymphocytic leukemia.
    Leukemia. 2016 Nov 4. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  262. GAIDZIK VI, Teleanu V, Papaemmanuil E, Weber D, et al
    RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
    Leukemia. 2016;30:2282.
    PubMed     Text format    


    October 2016
  263. MONTALBAN-BRAVO G, Huang X, Jabbour E, Borthakur G, et al
    A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  264. JULIUSSON G, Abrahamsson J, Lazarevic V, Antunovic P, et al
    Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  265. KHAN N, Hills RK, Virgo P, Couzens S, et al
    Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  266. BERGER G, van den Berg E, Sikkema-Raddatz B, Abbott KM, et al
    Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  267. STAMATOPOULOS B, Timbs A, Bruce D, Smith T, et al
    Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  268. OJAMIES PN, Kontro M, Edgren H, Ellonen P, et al
    Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.
    Leukemia. 2016 Oct 31. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  269. BARABE F, Gil L, Celton M, Bergeron A, et al
    Modeling human MLL-AF9 translocated acute myeloid leukemia from single donors reveals RET as a potential therapeutic target.
    Leukemia. 2016 Oct 26. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  270. LOHMANN G, Vasyutina E, Bloehdorn J, Reinart N, et al
    Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.
    Leukemia. 2016 Oct 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  271. LARRAYOZ M, Rose-Zerilli MJ, Kadalayil L, Parker H, et al
    Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial.
    Leukemia. 2016 Oct 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  272. PARK IK, Blum W, Baker SD, Caligiuri MA, et al
    E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia.
    Leukemia. 2016 Oct 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  273. XU B, Zhao Y, Wang X, Gong P, et al
    MZH29 is a novel potent inhibitor that overcomes drug resistance- FLT3 mutations in acute myeloid leukemia.
    Leukemia. 2016 Oct 24. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  274. XIN J, You D, Breslin P, Li J, et al
    Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway.
    Leukemia. 2016 Oct 17. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  275. WU M, Hamaker M, Li L, Small D, et al
    DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.
    Leukemia. 2016 Oct 17. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  276. NARAYAN N, Morenos L, Phipson B, Willis SN, et al
    Functionally distinct roles foar different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukemia.
    Leukemia. 2016 Oct 14. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  277. WAANDERS E, Scheijen B, Jongmans MC, Venselaar H, et al
    Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.
    Leukemia. 2016 Oct 13. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  278. MADAN V, Shyamsunder P, Han L, Mayakonda A, et al
    Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
    Leukemia. 2016 Oct 7. doi: 10.1038/leu.2016.
    PubMed     Text format    


  279. KATO M, Ishimaru S, Seki M, Yoshida K, et al
    Long-term outcome of six-month maintenance chemotherapy for acute lymphoblastic leukemia in children.
    Leukemia. 2016 Oct 4. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  280. VIJAYAKRISHNAN J, Kumar R, Henrion MY, Moorman AV, et al
    A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1.
    Leukemia. 2016 Oct 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    September 2016
  281. NIBOUREL O, Guihard S, Roumier C, Pottier N, et al
    Copy-number analysis identified new prognostic marker in acute myeloid leukemia.
    Leukemia. 2016 Sep 30. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  282. GALLETTI G, Caligaris-Cappio F, Bertilaccio MT
    B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia.
    Leukemia. 2016 Sep 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  283. BLUM W, Sanford BL, Klisovic R, DeAngelo DJ, et al
    Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: A phase 2 cancer and leukemia group B study (CALGB 10503).
    Leukemia. 2016 Sep 13. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  284. GEISSLER K, Jager E, Barna A, Alendar T, et al
    Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors.
    Leukemia. 2016 Sep 2. doi: 10.1038/leu.2016.
    PubMed     Text format    


  285. THIJSSEN R, Ter Burg J, van Bochove GG, de Rooij MF, et al
    The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
    Leukemia. 2016;30:1963.
    PubMed     Text format    


    August 2016
  286. ALATRASH G, Garber HR, Zhang M, Sukhumalchandra P, et al
    Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.
    Leukemia. 2016 Aug 30. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  287. MIMMI S, Vecchio E, Iaccino E, Rossi M, et al
    Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients.
    Leukemia. 2016 Aug 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  288. GANESAN S, Alex AA, Chendamarai E, Balasundaram N, et al
    Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Leukemia. 2016 Aug 18. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  289. CHEN Z, Shao C, Wang W, Zuo Z, et al
    Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Leukemia. 2016 Aug 18. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  290. PUI CH, Pei D, Raimondi SC, Coustan-Smith E, et al
    Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy.
    Leukemia. 2016 Aug 18. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  291. FANG Y, Yang Y, Hua C, Xu S, et al
    Rictor plays a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia.
    Leukemia. 2016 Aug 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  292. KONTRO M, Kumar A, Majumder MM, Eldfors S, et al
    HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
    Leukemia. 2016 Aug 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  293. GEISSLER J, Sharf G, Cugurovic J, Padua R, et al
    Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer.
    Leukemia. 2016 Aug 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  294. BOYSEN J, Nelson M, Magzoub G, Maiti GP, et al
    Dynamics of microvesicle generation in B cell chronic lymphocytic leukemia: Implication in disease progression.
    Leukemia. 2016 Aug 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  295. KHORASHAD JS, Tantravahi SK, Yan D, Mason CC, et al
    Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.
    Leukemia. 2016 Aug 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  296. HERR W, Eichinger Y, Beshay J, Bloetz A, et al
    HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
    Leukemia. 2016 Aug 1. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  297. TUBI LQ, Nunes SC, Brancalion A, Breatta ED, et al
    Protein kinase CK2 regulates AKT, NF-kappaB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.
    Leukemia. 2016 Aug 1. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  298. QORRAJ M, Bruns H, Bottcher M, Weigand L, et al
    The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.
    Leukemia. 2016 Aug 1. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    July 2016
  299. ELDFORS S, Kuusanmaki H, Kontro M, Majumder MM, et al
    Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.
    Leukemia. 2016 Jul 27. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  300. RUIZ MS, Medina M, Tapia I, Mordoh J, et al
    Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators.
    Leukemia. 2016 Jul 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  301. CRUICKSHANK MN, Ford J, Cheung LC, Heng J, et al
    Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.
    Leukemia. 2016 Jul 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  302. CORREIA NC, Arcangeli ML, Pflumio F, Barata JT, et al
    Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage.
    Leukemia. 2016 Jul 22. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  303. EISFELD AK, Kohlschmidt J, Mrozek K, Blachly JS, et al
    Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.
    Leukemia. 2016 Jul 20. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  304. KOERNER SP, Andre MC, Leibold JS, Kousis PC, et al
    An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
    Leukemia. 2016 Jul 20. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  305. SALEH LM, Wang W, Herman SE, Saba NS, et al
    Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
    Leukemia. 2016 Jul 19. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  306. JONES L, Carol H, Evans K, Richmond J, et al
    A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the pediatric preclinical testing program.
    Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  307. MANARA E, Basso G, Zampini M, Buldini B, et al
    Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.
    Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  308. PING N, Sun A, Song Y, Wang Q, et al
    Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia.
    Leukemia. 2016 Jul 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  309. SUN QY, Ding LW, Tan KT, Chien W, et al
    Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).
    Leukemia. 2016 Jul 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  310. THEIS F, Corbacioglu A, Gaidzik VI, Paschka P, et al
    Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: A study of the AML study group (AMLSG).
    Leukemia. 2016 Jul 4. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    June 2016
  311. ISHIYAMA KI, Kitawaki T, Sugimoto N, Sozu T, et al
    Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.
    Leukemia. 2016 Jun 28. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  312. ROSE D, Haferlach T, Schnittger S, Perglerova K, et al
    Subtype-specific patterns of molecular mutations in acute myeloid leukemia.
    Leukemia. 2016 Jun 10. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  313. LEE P, Bhansali R, Izraeli S, Hijiya N, et al
    The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with down syndrome.
    Leukemia. 2016 Jun 10. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  314. SCHIFFER CA
    Commentary on: 'Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia'.
    Leukemia. 2016 Jun 10. doi: 10.1038/leu.2016.
    PubMed     Text format    


  315. JAAKO P, Ugale A, Wahlestedt M, Velasco-Hernandez T, et al
    Induction of the 5S RNP-Mdm2-p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia.
    Leukemia. 2016 Jun 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  316. RICHINE BM, Virts EL, Bowling JD, Ramdas B, et al
    Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia.
    Leukemia. 2016 Jun 3. doi: 10.1038/leu.2016.
    PubMed     Text format    


    May 2016
  317. RASHIDI A, DiPersio JF, Westervelt P, Vij R, et al
    Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation?
    Leukemia. 2016 May 27. doi: 10.1038/leu.2016.
    PubMed     Text format    


  318. HAFERLACH T, Weber S, Konietschke R, Nadarajah N, et al
    Robustness of comprehensive DNA and RNA based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards.
    Leukemia. 2016 May 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  319. CHARAF L, Mahon FX, Lamrissi-Garcia I, Moranvillier I, et al
    Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia (CML) cells.
    Leukemia. 2016 May 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  320. HELLER G, Topakian T, Altenberger C, Cerny-Reiterer S, et al
    Next generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.
    Leukemia. 2016 May 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  321. ETCHIN J, Berezovskaya A, Conway AS, Galinsky IA, et al
    KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
    Leukemia. 2016 May 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  322. MITTON B, Chae HD, Hsu K, Dutta R, et al
    Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells.
    Leukemia. 2016 May 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  323. BASHFORD-ROGERS RJ, Nicolaou KA, Bartram J, Goulden NJ, et al
    Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse.
    Leukemia. 2016 May 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  324. MCCURDY SR, Iglehart BS, Batista DA, Gocke CD, et al
    Loss of the mismatched human leukocyte antigen haplotype in two acute Myelogenous leukemia relapses after haploidentical bone marrow transplantation with posttransplantation cyclophosphamide.
    Leukemia. 2016 May 23. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  325. IMAMURA T, Yano M, Asai D, Moriya-Saito A, et al
    IKZF1 deletion is enriched in pediatric B-cell precursor acute lymphoblastic leukemia patients showing prednisolone resistance.
    Leukemia. 2016 May 20. doi: 10.1038/leu.2016.
    PubMed     Text format    


  326. CERVANTES-GOMEZ F, Kumar Patel V, Bose P, Keating MJ, et al
    Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Leukemia. 2016 May 20. doi: 10.1038/leu.2016.
    PubMed     Text format    


  327. MORLEY AA
    Reporting results for deep molecular responses in chronic myeloid leukemia.
    Leukemia. 2016 May 17. doi: 10.1038/leu.2016.
    PubMed     Text format    


  328. CROSS NC, Hochhaus A
    Deep molecular response in chronic myeloid leukemia.
    Leukemia. 2016 May 13. doi: 10.1038/leu.2016.
    PubMed     Text format    


  329. CANTE-BARRETT K, Spijkers-Hagelstein JA, Buijs-Gladdines JG, Uitdehaag JC, et al
    MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
    Leukemia. 2016 May 13. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  330. WALLAERT A, Durinck K, Van Loocke W, Van de Walle I, et al
    Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia.
    Leukemia. 2016 May 10. doi: 10.1038/leu.2016.
    PubMed     Text format    


  331. GAIDZIK VI, Teleanu V, Papaemmanuil E, Weber D, et al
    RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
    Leukemia. 2016 May 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  332. CARDOSO SR, Ryan G, Walne AJ, Ellison A, et al
    Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  333. OTHUS M, Wood BL, Stirewalt DL, Estey EH, et al
    Effect of measurable ("minimal") residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  334. SAUSSELE S, Richter J, Hochhaus A, Mahon FX, et al
    The concept of treatment-free remission in chronic myeloid leukemia.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  335. BRODERSEN LE, Alonzo TA, Menssen AJ, Gerbing RB, et al
    A recurrent immunophenotype at diagnosis independently identifies high risk pediatric acute myeloid leukemia: A report from children's oncology group.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  336. ZHENG Y, Zhang H, Wang Y, Li X, et al
    Loss of Dnmt3b accelerates MLL-AF9 leukemia progression.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  337. HJORTH-HANSEN H, Stentoft J, Richter J, Koskenvesa P, et al
    Safety and efficacy of the combination of pegylated interferon-alpha2b and dasatinib in newly diagnosed chronic phase chronic myeloid leukemia patients.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  338. CICCONI L, Divona M, Ciardi C, Ottone T, et al
    PML-RARalpha kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukemia treated with ATRA and ATO or ATRA and chemotherapy.
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  339. MAURER C, Langerbeins P, Bahlo J, Cramer P, et al
    Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with chronic lymphocytic leukemia (CLL).
    Leukemia. 2016 May 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


    April 2016
  340. SONTAKKE P, Carretta M, Jaques J, Brouwers-Vos AZ, et al
    Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold based xenograft model.
    Leukemia. 2016 Apr 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  341. HALBACH S, Kohler M, Uhl FM, Huber J, et al
    Gab2 is essential for Bcr-Abl mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model.
    Leukemia. 2016 Apr 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  342. GEKAS C, D'Altri T, Aligue R, Gonzalez J, et al
    beta-Catenin is required for T cell leukemia initiation and MYC transcription downstream of Notch1.
    Leukemia. 2016 Apr 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  343. WATANABE-SMITH K, Tognon C, Tyner JW, Meijerink JP, et al
    Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.
    Leukemia. 2016 Apr 27. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  344. WISEMAN DH, Williams EL, Wilks DP, Leong HS, et al
    Frequent reconstitution of IDH2 mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia.
    Leukemia. 2016 Apr 27. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  345. KONG G, Chang YI, You X, Ranheim EA, et al
    The ability of endogenous Nras oncogenes to initiate leukemia is codon-dependent.
    Leukemia. 2016 Apr 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  346. WANG Y, Gao A, Zhao H, Lu P, et al
    Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1alpha/CCL3.
    Leukemia. 2016 Apr 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  347. DAL BO M, Bulian P, Bomben R, Zucchetto A, et al
    CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.
    Leukemia. 2016 Apr 25. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  348. MADAN V, Shyamsunder P, Han L, Mayakonda A, et al
    Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
    Leukemia. 2016 Apr 11. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  349. DARIA D, Kirsten N, Muranyi A, Mulaw M, et al
    GPR56 contributes to the development of acute myeloid leukemia in mice.
    Leukemia. 2016 Apr 11. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  350. YU C, Dasmahapatra G, Dent P, Grant S, et al
    Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
    Leukemia. 2016 Apr 8. doi: 10.1038/leu.2016.
    PubMed     Text format    


  351. DINMOHAMED AG, Brink M, Visser O, Jongen-Lavrencic M, et al
    Population-based analyses among 184 patients diagnosed with large granular lymphocyte leukemia in the Netherlands between 2001 and 2013.
    Leukemia. 2016 Apr 8. doi: 10.1038/leu.2016.
    PubMed     Text format    


  352. MARIANI SA, Minieri V, De Dominici M, Iacobucci I, et al
    CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia.
    Leukemia. 2016 Apr 5. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  353. BERLIN C, Kowalewski DJ, Schuster H, Mirza N, et al
    Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
    Leukemia. 2016;30:1003-4.
    PubMed     Text format    


  354. PARDANANI A, Reichard KK, Zblewski D, Abdelrahman RA, et al
    CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value.
    Leukemia. 2016;30:914-8.
    PubMed     Text format     Abstract available


  355. MARTINEZ-MORENO M, Leiva M, Aguilera-Montilla N, Sevilla-Movilla S, et al
    In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by alpha4beta1 cytoplasmic-binding proteins.
    Leukemia. 2016;30:861-72.
    PubMed     Text format     Abstract available


  356. SCHEMIONEK M, Herrmann O, Reher MM, Chatain N, et al
    Mtss1 is a critical epigenetically regulated tumor suppressor in CML.
    Leukemia. 2016;30:823-32.
    PubMed     Text format     Abstract available


  357. WAANDERS E, Hebeda KM, Kamping EJ, Groenen PJ, et al
    Independent development of lymphoid and histiocytic malignancies from a shared early precursor.
    Leukemia. 2016;30:955-8.
    PubMed     Text format    


    March 2016
  358. HUANG W, Luan CH, Hjort EE, Bei L, et al
    The role of Fas-associated phosphatase 1 in leukemia stem cell-persistence during tyrosine kinase inhibitor-treatment of chronic myeloid leukemia.
    Leukemia. 2016 Mar 17. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  359. TSAI CH, Hou HA, Tang JL, Liu CY, et al
    Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.
    Leukemia. 2016 Mar 17. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  360. GONDEK LP, Zheng G, Ghiaur G, DeZern AE, et al
    Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.
    Leukemia. 2016 Mar 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  361. MATLAWSKA-WASOWSKA K, Kang H, Devidas M, Wen J, et al
    MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: A children's oncology group study.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  362. BRAUN M, Qorraj M, Buttner M, Klein FA, et al
    CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  363. YOUNG SS, Tucker T, Bosdet I, Karsan A, et al
    Estimating deep molecular responses in chronic myelogenous leukemia: a Bayesian approach.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format    


  364. WANG X, Lin Q, Lv F, Liu N, et al
    LG-362B targets PML-RARalpha and blocks ATRA resistance of acute promyelocytic leukemia.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  365. GU Y, Zheng W, Zhang J, Gan X, et al
    Aberrant activation of CaMKIIgamma accelerates chronic myeloid leukemia blast crisis.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  366. HAYAKAWA K, Formica AM, Colombo MJ, Shinton SA, et al
    Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  367. WAGLE M, Eiring AM, Wongchenko M, Lu S, et al
    A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  368. GUNNARSSON N, Hoglund M, Stenke L, Wallberg-Jonsson S, et al
    Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.
    Leukemia. 2016 Mar 8. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  369. PANG SH, Minnich M, Gangatirkar P, Zheng Z, et al
    PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia.
    Leukemia. 2016 Mar 2. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  370. PINZ K, Liu H, Golightly M, Jares A, et al
    Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.
    Leukemia. 2016;30:701-7.
    PubMed     Text format     Abstract available


  371. HANNA BS, McClanahan F, Yazdanparast H, Zaborsky N, et al
    Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.
    Leukemia. 2016;30:570-9.
    PubMed     Text format     Abstract available


  372. SALLMAN DA, Komrokji R, Vaupel C, Cluzeau T, et al
    Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Leukemia. 2016;30:666-73.
    PubMed     Text format     Abstract available


  373. GOYAMA S, Schibler J, Gasilina A, Shrestha M, et al
    UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
    Leukemia. 2016;30:728-39.
    PubMed     Text format     Abstract available


  374. SAITOH Y, Hamano A, Mochida K, Kakeya A, et al
    A20 targets caspase-8 and FADD to protect HTLV-I-infected cells.
    Leukemia. 2016;30:716-27.
    PubMed     Text format     Abstract available


  375. RUMINY P, Marchand V, Buchbinder N, Larson T, et al
    Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia.
    Leukemia. 2016;30:757-60.
    PubMed     Text format    


  376. WU H, Hu C, Wang A, Weisberg EL, et al
    Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.
    Leukemia. 2016;30:754-7.
    PubMed     Text format    


    February 2016
  377. LUCAS CM, Milani M, Butterworth M, Carmell N, et al
    High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-X in chronic myeloid leukemia.
    Leukemia. 2016 Feb 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  378. ZHOU Y, Othus M, Araki D, Wood BL, et al
    Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
    Leukemia. 2016 Feb 29. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  379. OTHUS M, Mukherjee S, Sekeres MA, Godwin J, et al
    Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.
    Leukemia. 2016 Feb 29. doi: 10.1038/leu.2016.
    PubMed     Text format    


  380. HIRSCH P, Mamez AC, Belhocine R, Lapusan S, et al
    Clonal history of a cord blood donor cell leukemia with pre-natal somatic JAK2 V617F mutation.
    Leukemia. 2016 Feb 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  381. BOBBALA D, Kandhi R, Chen XL, Mayhue M, et al
    Interleukin-15 deficiency promotes the development of T-cell acute lymphoblastic leukemia in non-obese diabetes mice with severe combined immunodeficiency.
    Leukemia. 2016 Feb 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  382. ALVAREZ-TWOSE I, Martinez-Barranco P, Gotlib J, Garcia-Montero A, et al
    Complete response to gemtuzumab-ozogamicin in a patient with refractory mast cell leukemia.
    Leukemia. 2016 Feb 15. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  383. SOVERINI S, De Benedittis C, Papayannidis C, Polakova KM, et al
    Clinical impact of low burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
    Leukemia. 2016 Feb 12. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  384. KRUG U, Berdel WE, Gale RP, Haferlach C, et al
    Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.
    Leukemia. 2016 Feb 9. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  385. MIRANDA MB, Lauseker M, Kraus MP, Proetel U, et al
    Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment- long-term observation in CML Study IV.
    Leukemia. 2016 Feb 9. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  386. JAKOBS A, Uttarkar S, Schomburg C, Steinmann S, et al
    An isoform-specific C/EBPbeta inhibitor targets acute myeloid leukemia cells.
    Leukemia. 2016 Feb 8. doi: 10.1038/leu.2016.
    PubMed     Text format    


  387. KOHRER S, Havranek O, Seyfried F, Hurtz C, et al
    Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1, and MYC, and can be targeted by SYK inhibition.
    Leukemia. 2016 Feb 5. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  388. CHEN Z, Cortes JE, Jorgensen JL, Wang W, et al
    Differential impact of additional chromosomal abnormalities in myeloid versus lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Leukemia. 2016 Feb 3. doi: 10.1038/leu.2016.
    PubMed     Text format    


  389. HOCHHAUS A, Saglio G, Hughes TP, Larson RA, et al
    Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
    Leukemia. 2016 Feb 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  390. DIELSCHNEIDER RF, Eisenstat H, Mi S, Curtis JM, et al
    Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism.
    Leukemia. 2016 Feb 3. doi: 10.1038/leu.2016.
    PubMed     Text format     Abstract available


  391. RADIVOYEVITCH T, Sachs RK, Gale RP, Molenaar RJ, et al
    Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.
    Leukemia. 2016;30:285-94.
    PubMed     Text format     Abstract available


  392. MUHLBACHER V, Haferlach T, Kern W, Zenger M, et al
    Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis.
    Leukemia. 2016;30:318-24.
    PubMed     Text format     Abstract available


  393. SOLOMON BM, Chaffee KG, Moreira J, Schwager SM, et al
    Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis.
    Leukemia. 2016;30:331-6.
    PubMed     Text format     Abstract available


  394. JAYAVELU AK, Muller JP, Bauer R, Bohmer SA, et al
    NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.
    Leukemia. 2016;30:473-83.
    PubMed     Text format     Abstract available


  395. MIDDEKE JM, Herbst R, Parmentier S, Bug G, et al
    Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.
    Leukemia. 2016;30:261-7.
    PubMed     Text format     Abstract available


  396. KRUPKA C, Kufer P, Kischel R, Zugmaier G, et al
    Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
    Leukemia. 2016;30:484-91.
    PubMed     Text format     Abstract available


  397. BENEDETTI D, Tissino E, Caldana C, Dal Bo M, et al
    Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?
    Leukemia. 2016;30:513-7.
    PubMed     Text format    


    January 2016
  398. LIM M, Pang Y, Ma S, Hao S, et al
    Altered mesenchymal niche cells impede generation of normal hematopoietic progenitor cells in leukemic bone marrow.
    Leukemia. 2016;30:154-62.
    PubMed     Text format     Abstract available


  399. HERMANOVA I, Arruabarrena-Aristorena A, Valis K, Nuskova H, et al
    Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells.
    Leukemia. 2016;30:209-18.
    PubMed     Text format     Abstract available


  400. CUI X, Zhang L, Magli AR, Catera R, et al
    Cytoplasmic myosin-exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability.
    Leukemia. 2016;30:74-85.
    PubMed     Text format     Abstract available


  401. ETCHIN J, Montero J, Berezovskaya A, Le BT, et al
    Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.
    Leukemia. 2016;30:190-9.
    PubMed     Text format     Abstract available


  402. KOCZULA KM, Ludwig C, Hayden R, Cronin L, et al
    Metabolic plasticity in CLL: adaptation to the hypoxic niche.
    Leukemia. 2016;30:65-73.
    PubMed     Text format     Abstract available


  403. NOWEK K, Sun SM, Bullinger L, Bindels EM, et al
    Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.
    Leukemia. 2016;30:229-37.
    PubMed     Text format     Abstract available


  404. SAULEP-EASTON D, Vincent FB, Quah PS, Wei A, et al
    The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells.
    Leukemia. 2016;30:163-72.
    PubMed     Text format     Abstract available


  405. SIVE JI, Basilico S, Hannah R, Kinston SJ, et al
    Genome-scale definition of the transcriptional programme associated with compromised PU.1 activity in acute myeloid leukaemia.
    Leukemia. 2016;30:14-23.
    PubMed     Text format     Abstract available


  406. SEVCIKOVA K, Zhuang Z, Garcia-Manero G, Alvarez RH, et al
    Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.
    Leukemia. 2016;30:242-7.
    PubMed     Text format    


    December 2015
  407. MARKE R, Havinga J, Cloos J, Demkes M, et al
    Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2015 Dec 29. doi: 10.1038/leu.2015.
    PubMed     Text format    


  408. JENA N, Sheng J, Hu JK, Li W, et al
    CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T cell acute lymphoblastic leukemia.
    Leukemia. 2015 Dec 28. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  409. DUTTA S, Krause A, Vosberg S, Herold T, et al
    The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models.
    Leukemia. 2015 Dec 21. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  410. CHANG E, Ganguly S, Rajkhowa T, Gocke CD, et al
    The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.
    Leukemia. 2015 Dec 21. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  411. ESTEY E, Othus M, Lee SJ, Appelbaum FR, et al
    New drug approvals in acute myeloid leukemia: what's the best end point?
    Leukemia. 2015 Dec 18. doi: 10.1038/leu.2015.
    PubMed     Text format    


  412. PAN MM, Zhang QY, Wang YY, Liu P, et al
    Human NUP98-IQCG fusion protein induces acute myelomonocytic leukemia in mice by dysregulating the Hox/Pbx3 pathway.
    Leukemia. 2015 Dec 17. doi: 10.1038/leu.2015.
    PubMed     Text format    


  413. ZONG H, Sen S, Zhang G, Mu C, et al
    In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche.
    Leukemia. 2015 Dec 16. doi: 10.1038/leu.2015.
    PubMed     Text format    


  414. BHATNAGAR B, Blachly JS, Kohlschmidt J, Eisfeld AK, et al
    Clinical features, and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).
    Leukemia. 2015 Dec 16. doi: 10.1038/leu.2015.
    PubMed     Text format    


  415. MASON CC, Khorashad JS, Tantravahi SK, Kelley TW, et al
    Age-related mutations and chronic myelomonocytic leukemia.
    Leukemia. 2015 Dec 9. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  416. GENTILE M, Shanafelt TD, Cutrona G, Molica S, et al
    A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients.
    Leukemia. 2015 Dec 9. doi: 10.1038/leu.2015.
    PubMed     Text format    


  417. TOSELLO V, Bordin F, Yu J, Agnusdei V, et al
    Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein (XIAP) degradation.
    Leukemia. 2015 Dec 9. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  418. RAWSTRON AC, Fazi C, Agathangelidis A, Villamor N, et al
    A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study.
    Leukemia. 2015 Dec 7. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  419. SONG C, Pan X, Ge Z, Gowda C, et al
    Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II (CK2) in leukemia.
    Leukemia. 2015 Dec 7. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  420. ROUCE RH, Shaim H, Sekine T, Weber G, et al
    The TGF-beta/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B acute lymphoblastic leukemia.
    Leukemia. 2015 Dec 1. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


    November 2015
  421. GEYH S, Rodriguez-Paredes M, Jager P, Khandanpour C, et al
    Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia.
    Leukemia. 2015 Nov 25. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  422. SINHA S, Boysen J, Nelson M, Warner SL, et al
    Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells.
    Leukemia. 2015 Nov 24. doi: 10.1038/leu.2015.
    PubMed     Text format    


  423. ZABRISKIE MS, Eide CA, Yan D, Vellore NA, et al
    Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.
    Leukemia. 2015 Nov 19. doi: 10.1038/leu.2015.
    PubMed     Text format    


  424. DESOUTTER J, Gay J, Berthon C, Ades L, et al
    Molecular prognostic factors in acute myeloid leukemia (AML) receiving first-line therapy with azacitidine.
    Leukemia. 2015 Nov 19. doi: 10.1038/leu.2015.
    PubMed     Text format    


  425. BALSS J, Thiede C, Bochtler T, Okun JG, et al
    Pretreatment D-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
    Leukemia. 2015 Nov 19. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  426. CHEN SS, Chang BY, Chang S, Tong T, et al
    BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.
    Leukemia. 2015 Nov 19. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


  427. MORITA K, Masamoto Y, Kataoka K, Koya J, et al
    BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4.
    Leukemia. 2015;29:2248-56.
    PubMed     Text format     Abstract available


  428. FORD AM, Mansur MB, Furness CL, van Delft FW, et al
    Protracted dormancy of pre-leukemic stem cells.
    Leukemia. 2015;29:2202-7.
    PubMed     Text format     Abstract available


  429. ZHAO Q, Ahmed M, Tassev DV, Hasan A, et al
    Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
    Leukemia. 2015;29:2238-47.
    PubMed     Text format     Abstract available


  430. MOLENAAR RJ, Thota S, Nagata Y, Patel B, et al
    Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.
    Leukemia. 2015;29:2134-42.
    PubMed     Text format     Abstract available


    October 2015
  431. WATKINS DB, Hughes TP, White DL
    OCT1 and imatinib transport in CML: is it clinically relevant?
    Leukemia. 2015;29:1960-9.
    PubMed     Text format     Abstract available


  432. DEVEAU AP, Forrester AM, Coombs AJ, Wagner GS, et al
    Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98-HOXA9-induced myeloid disease.
    Leukemia. 2015;29:2086-97.
    PubMed     Text format     Abstract available


  433. VASYUTINA E, Boucas JM, Bloehdorn J, Aszyk C, et al
    The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
    Leukemia. 2015;29:2003-14.
    PubMed     Text format     Abstract available


  434. LI Z, Stolzel F, Onel K, Sukhanova M, et al
    Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.
    Leukemia. 2015;29:2113-6.
    PubMed     Text format    


  435. HAHN CN, Ross DM, Feng J, Beligaswatte A, et al
    A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone.
    Leukemia. 2015;29:2101-4.
    PubMed     Text format    


    September 2015
  436. BERNAL T, Martinez-Camblor P, Sanchez-Garcia J, de Paz R, et al
    Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
    Leukemia. 2015;29:1875-81.
    PubMed     Text format     Abstract available


  437. BALAKRISHNAN K, Peluso M, Fu M, Rosin NY, et al
    The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
    Leukemia. 2015;29:1811-22.
    PubMed     Text format     Abstract available


  438. PARRISH C, Scott GB, Migneco G, Scott KJ, et al
    Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.
    Leukemia. 2015;29:1799-810.
    PubMed     Text format     Abstract available


  439. CHANG YI, You X, Kong G, Ranheim EA, et al
    Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Leukemia. 2015;29:1847-56.
    PubMed     Text format     Abstract available


  440. COLES SJ, Gilmour MN, Reid R, Knapper S, et al
    The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.
    Leukemia. 2015;29:1952-4.
    PubMed     Text format    


  441. KARACHUNSKIY A, Roumiantseva J, Lagoiko S, Buhrer C, et al
    Efficacy and toxicity of dexamethasone vs methylprednisolone-long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002.
    Leukemia. 2015;29:1955-8.
    PubMed     Text format    


    July 2015
  442. RONCERO AM, Lopez-Nieva P, Cobos-Fernandez MA, Villa-Morales M, et al
    Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development.
    Leukemia. 2015 Jul 28. doi: 10.1038/leu.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: